Successful maintenance therapy with tocilizumab for severe acute liver failure associated with adult-onset still’s disease

References

• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19:424–430.
   PubMed Web of Science ®Google Scholar
• Asanuma YF, Mimura T, Tsuboi H, et al. Nationwide epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol. 2015;25(3):393–400. doi:10.3109/14397595.2014.974881.
   PubMed Web of Science ®Google Scholar
• Muller R, Briantais A, Faucher B, et al. Acute severe hepatitis in adult-onset Still’s disease: case report and comprehensive review of a life-threatening manifestation. Clin Rheumatol. 2021;40(6):2467–2476. doi:10.1007/s10067-020-05383-y.
   Web of Science ®Google Scholar
• Kurokawa M, Hioki T, Aoyagi T, et al. Clinicopathologic features of adult-onset still’s disease complicated by severe liver injury. Intern Med. 2024;63(4):503–511. doi:10.2169/internalmedicine.2043-23.
   Web of Science ®Google Scholar
• Nagashima T, Aoki Y, Onishi S, et al. Steroid-refractory severe hepatic failure in adult onset Still’s disease responding to cyclosporine. Clin Rheumatol. 2008;27(11):1451–1453. doi:10.1007/s10067-008-0950-9.
   Web of Science ®Google Scholar
• Nakamura H, Fujieda Y, Tarumi M, et al. Calcineurin inhibitors for adult-onset Still’s disease: a multicentre retrospective cohort study. Clin Exp Rheumatol. 2020;38(Suppl 127):11–16.
   PubMedGoogle Scholar
• Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720–1729. doi:10.1136/annrheumdis-2018-213920.
   PubMed Web of Science ®Google Scholar
• Adachi S, Takase-Minegishi K, Maeda A, et al. Risk of macrophage activation syndrome in patients with adult-onset still’s disease treated with IL-1 and IL-6 inhibitors: a meta-analysis and single-center experience. Rheumatol Ther. 2023;10(6):1623–1636. doi:10.1007/s40744-023-00600-x.
   Web of Science ®Google Scholar
• Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41(9):805–812. doi:10.1111/j.1872-034X.2011.00860.x.
   Web of Science ®Google Scholar
• Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–618. doi:10.1038/s41584-018-0081-x.
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Esdaile JM, Medsger TA, et al. A controlled study of the long-term prognosis of adult Still’s disease. Am J Med. 1995;98(4):384–388. doi:10.1016/s0002-9343(99)80318-0.
   Web of Science ®Google Scholar
• Chi H, Wang Z, Meng J, et al. A cohort study of liver involvement in patients with adult-onset still’s disease: prevalence, characteristics and impact on prognosis. Front Med (Lausanne). 2020;7:621005. doi:10.3389/fmed.2020.621005.
   Web of Science ®Google Scholar
• Leavis HL, van Daele PLA, Mulders-Manders C, et al. Management of adult-onset Still’s disease: evidence- and consensus-based recommendations by experts. Rheumatology. 2023;63(6):1656–1663. doi:10.1093/rheumatology/kead461.
   Web of Science ®Google Scholar
• Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22(5):712–719. doi:10.3109/s10165-011-0569-6.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Manara M, Bortoluzzi A, et al. Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Res Ther. 2019;21(1):275. doi:10.1186/s13075-019-2021-9.
   Web of Science ®Google Scholar
• Ruscitti P, Cantarini L, Nigrovic PA, et al. Recent advances and evolving concepts in Still’s disease. Nat Rev Rheumatol. 2024;20(2):116–132. doi:10.1038/s41584-023-01065-6.
   Web of Science ®Google Scholar
• Priori R, Barone F, Alessandri C, et al. Markedly increased IL-18 liver expression in adult-onset Still’s disease-related hepatitis. Rheumatology. 2011;50(4):776–780. doi:10.1093/rheumatology/keq397.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Masuda K, et al. Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. Inflamm Regen. 2013;33(1):054–065. doi:10.2492/inflammregen.33.054.
   Google Scholar
• Shimojima Y, Ichikawa T, Kishida D, et al. Circulating regulatory T cells in adult-onset Still’s disease: focusing on their plasticity and stability. Clin Exp Immunol. 2021;206(2):184–195. doi:10.1111/cei.13648.
   Web of Science ®Google Scholar
• Yoshida H, Magi M, Tamai H, et al. Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis. Rheumatology. 2024;1–10. doi:10.1093/rheumatology/keae196.
   Web of Science ®Google Scholar
• Sakai R, Ito M, Yoshimoto K, et al. Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4+ Treg axis during remission of crescentic glomerulonephritis. Clin Transl Immunology. 2020;9(11):e1203. doi:10.1002/cti2.1203.
   Web of Science ®Google Scholar
• Kikuchi J, Hashizume M, Kaneko Y, et al. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther. 2015;17(1):10. doi:10.1186/s13075-015-0526-4.
   PubMedGoogle Scholar
• Scholz GA, Fux M, Christ L, et al. Divergent regulatory T cell responses to high-dose methylprednisolone and tocilizumab in giant cell arteritis. J Autoimmun. 2022;133:102909. doi:10.1016/j.jaut.2022.102909.
   Web of Science ®Google Scholar